NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ZBIO

Zenas Biopharma Inc

Jul 03 • 02:20PM ET

10.03

Dollar change -0.19
Percentage change -1.86	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IWN VTWO SCHA FESM IWC SBIO RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.98	Insider Own	75.62%	Shs Outstand	41.82M	Perf Week	-1.18%
Market Cap	419.60M	Forward P/E	-	EPS next Y	-3.98	Insider Trans	0.11%	Shs Float	10.20M	Perf Month	5.36%
Enterprise Value	108.45M	PEG	-	EPS next Q	-1.04	Inst Own	32.99%	Short Float	48.14%	Perf Quarter	18.98%
Income	-162.76M	P/S	27.97	EPS this Y	64.57%	Inst Trans	4.31%	Short Ratio	25.63	Perf Half Y	11.57%
Sales	15.00M	P/B	1.48	EPS next Y	5.63%	ROA	-85.03%	Short Interest	4.91M	Perf YTD	22.47%
Book/sh	6.80	P/C	1.34	EPS next 5Y	31.58%	ROE	-115.47%	52W High	26.25 -61.79%	Perf Year	-
Cash/sh	7.47	P/FCF	-	EPS past 3/5Y	-9.85% -	ROIC	-57.18%	52W Low	5.83 72.04%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.15%	Volatility	10.60% 9.35%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7.23	EPS Y/Y TTM	-	Oper. Margin	-1157.59%	ATR (14)	0.99	Perf 10Y	-
Dividend Ex-Date	Dec 24, 2019	Quick Ratio	6.47	Sales Y/Y TTM	-	Profit Margin	-1085.07%	RSI (14)	50.05	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.47	EPS Q/Q	-10.71%	SMA20	-2.14%	Beta	-	Target Price	31.57
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-1.84%	Rel Volume	0.76	Prev Close	10.22
Employees	130	LT Debt/Eq	0.00	Earnings	May 15 BMO	SMA200	-12.73%	Avg Volume	191.61K	Price	10.03
IPO	Sep 13, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	29.43% 499.99%	Trades		Volume	145,704	Change	-1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
05:45AM	Loading…
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
02:54PM	Loading…
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOULDER LEON O JR	Chief Executive Officer	Feb 18 '25	Buy	6.67	25,000	166,750	266,155	Feb 19 04:01 PM
Xiao Ting	Director	Feb 07 '25	Buy	7.76	10,000	77,600	47,000	Feb 11 04:20 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 04 '24	Buy	9.98	45,000	449,100	241,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 03 '24	Buy	10.76	25,000	269,000	196,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 18 '24	Buy	15.00	7,500	112,500	168,655	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 19 '24	Buy	14.57	2,500	36,425	171,155	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 18 '24	Buy	17.91	10,000	179,100	1,662,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 20 '24	Buy	18.45	5,000	92,270	1,672,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 19 '24	Buy	17.89	5,000	89,450	1,667,039	Sep 20 06:34 PM
Enavate Sciences GP, LLC	10% Owner	Sep 16 '24	Buy	17.00	882,353	15,000,001	3,761,359	Sep 18 04:15 PM
Lu Hongbo	Director	Sep 13 '24	Buy	17.00	58,823	999,991	58,823	Sep 17 07:52 PM
ENRIGHT PATRICK G	Director	Sep 16 '24	Buy	17.00	440,000	7,480,000	774,530	Sep 16 08:57 PM
Nunn Jason Raleigh	Director	Sep 16 '24	Buy	17.00	882,352	14,999,984	1,946,564	Sep 16 08:54 PM
Fairmount Funds Management LLC	Director	Sep 16 '24	Buy	17.00	300,000	5,100,000	1,604,891	Sep 16 08:54 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 16 '24	Buy	17.00	2,235,294	37,999,998	1,946,564	Sep 16 08:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZBIO

Zenas Biopharma Inc

Upgrade your FINVIZ experience